Gast ::
| Hauptseite > Publikationsdatenbank > Mars Shot for Nuclear Medicine, Molecular Imaging, and Molecularly Targeted Radiopharmaceutical Therapy > print |
| Hauptseite > Publikationsdatenbank > Mars Shot for Nuclear Medicine, Molecular Imaging, and Molecularly Targeted Radiopharmaceutical Therapy > print |
| 001 | 904383 | ||
| 005 | 20230123101905.0 | ||
| 024 | 7 | _ | |a 10.2967/jnumed.120.253450 |2 doi |
| 024 | 7 | _ | |a 0022-3123 |2 ISSN |
| 024 | 7 | _ | |a 0097-9058 |2 ISSN |
| 024 | 7 | _ | |a 0161-5505 |2 ISSN |
| 024 | 7 | _ | |a 1535-5667 |2 ISSN |
| 024 | 7 | _ | |a 2159-662X |2 ISSN |
| 024 | 7 | _ | |a 2128/32273 |2 Handle |
| 024 | 7 | _ | |a 33334911 |2 pmid |
| 024 | 7 | _ | |a WOS:000621928600004 |2 WOS |
| 037 | _ | _ | |a FZJ-2021-05953 |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Wahl, Richard L. |0 P:(DE-HGF)0 |b 0 |e Corresponding author |
| 245 | _ | _ | |a Mars Shot for Nuclear Medicine, Molecular Imaging, and Molecularly Targeted Radiopharmaceutical Therapy |
| 260 | _ | _ | |a New York, NY |c 2021 |b Soc. |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1667392712_31190 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a AbstractThe Society of Nuclear Medicine and Molecular Imaging created the Value Initiative in 2017 as a major component of its strategic plan to further demonstrate the value of molecular imaging and molecularly targeted radiopharmaceutical therapy to patients, physicians, payers, and funding agencies. The research and discovery domain, 1 of 5 under the Value Initiative, has a goal of advancing the research and development of diagnostic and therapeutic nuclear medicine. Research and discovery efforts and achievements are essential to ensure a bright future for NM and to translate science to practice. Given the remarkable progress in the field, leaders from the research and discovery domain and society councils identified 5 broad areas of opportunity with potential for substantive growth and clinical impact. This article discusses these 5 growth areas, identifying specific areas of particularly high importance for future study and development. As there was an understanding that goals should be both visionary yet achievable, this effort was called the Mars shot for nuclear medicine.Keywords: artificial intelligence; molecular imaging; neuroimaging; radiopharmaceutical therapy; theranostics. |
| 536 | _ | _ | |a 5253 - Neuroimaging (POF4-525) |0 G:(DE-HGF)POF4-5253 |c POF4-525 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, Journals: juser.fz-juelich.de |
| 700 | 1 | _ | |a Chareonthaitawee, Panithaya |0 P:(DE-HGF)0 |b 1 |
| 700 | 1 | _ | |a Clarke, Bonnie |0 P:(DE-HGF)0 |b 2 |
| 700 | 1 | _ | |a Drzezga, Alexander |0 P:(DE-Juel1)177611 |b 3 |
| 700 | 1 | _ | |a Lindenberg, Liza |0 P:(DE-HGF)0 |b 4 |
| 700 | 1 | _ | |a Rahmim, Arman |0 P:(DE-HGF)0 |b 5 |
| 700 | 1 | _ | |a Thackeray, James |0 P:(DE-HGF)0 |b 6 |
| 700 | 1 | _ | |a Ulaner, Gary A. |0 P:(DE-HGF)0 |b 7 |
| 700 | 1 | _ | |a Weber, Wolfgang |0 P:(DE-HGF)0 |b 8 |
| 700 | 1 | _ | |a Zukotynski, Katherine |0 P:(DE-HGF)0 |b 9 |
| 700 | 1 | _ | |a Sunderland, John |0 P:(DE-HGF)0 |b 10 |e Corresponding author |
| 773 | _ | _ | |a 10.2967/jnumed.120.253450 |g Vol. 62, no. 1, p. 6 - 14 |0 PERI:(DE-600)2040222-3 |n 1 |p 6 - 14 |t Journal of nuclear medicine |v 62 |y 2021 |x 0022-3123 |
| 856 | 4 | _ | |u https://juser.fz-juelich.de/record/904383/files/6.full.pdf |y OpenAccess |
| 909 | C | O | |o oai:juser.fz-juelich.de:904383 |p openaire |p open_access |p VDB |p driver |p dnbdelivery |
| 910 | 1 | _ | |a Mallinckrodt Institute of Radiology, Washington University St. Louis, Missouri |0 I:(DE-HGF)0 |b 0 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota |0 I:(DE-HGF)0 |b 1 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Research and Discovery, Society of Nuclear Medicine and Molecular Imaging, Reston, Virginia |0 I:(DE-HGF)0 |b 2 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 3 |6 P:(DE-Juel1)177611 |
| 910 | 1 | _ | |a Department of Nuclear Medicine, University of Cologne, Cologne, Germany |0 I:(DE-HGF)0 |b 3 |6 P:(DE-Juel1)177611 |
| 910 | 1 | _ | |a German Center for Neurodegenerative Diseases, Bonn-Cologne, Germany |0 I:(DE-HGF)0 |b 3 |6 P:(DE-Juel1)177611 |
| 910 | 1 | _ | |a Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland |0 I:(DE-HGF)0 |b 4 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Departments of Radiology and Physics, University of British Columbia, Vancouver, British Columbia, Canada |0 I:(DE-HGF)0 |b 5 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Department of Integrative Oncology, BC Cancer Research Institute, Vancouver, British Columbia, Canada |0 I:(DE-HGF)0 |b 5 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Department of Nuclear Medicine, Hannover Medical School, Hannover, Germany |0 I:(DE-HGF)0 |b 6 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York |0 I:(DE-HGF)0 |b 7 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Molecular Imaging and Therapy, Hoag Cancer Center, Newport Beach, California |0 I:(DE-HGF)0 |b 7 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Department of Nuclear Medicine, Technical University Munich, Munich, Germany |0 I:(DE-HGF)0 |b 8 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Departments of Medicine and Radiology, McMaster University, Hamilton, Ontario, Canada |0 I:(DE-HGF)0 |b 9 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Departments of Radiology and Physics, University of Iowa, Iowa City, Iowa |0 I:(DE-HGF)0 |b 10 |6 P:(DE-HGF)0 |
| 913 | 1 | _ | |a DE-HGF |b Key Technologies |l Natural, Artificial and Cognitive Information Processing |1 G:(DE-HGF)POF4-520 |0 G:(DE-HGF)POF4-525 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-500 |4 G:(DE-HGF)POF |v Decoding Brain Organization and Dysfunction |9 G:(DE-HGF)POF4-5253 |x 0 |
| 914 | 1 | _ | |y 2022 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2021-01-27 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2021-01-27 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2021-01-27 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2021-01-27 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2021-01-27 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b J NUCL MED : 2019 |d 2021-01-27 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2021-01-27 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2021-01-27 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2021-01-27 |
| 915 | _ | _ | |a OpenAccess |0 StatID:(DE-HGF)0510 |2 StatID |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b J NUCL MED : 2019 |d 2021-01-27 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2021-01-27 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0320 |2 StatID |b PubMed Central |d 2021-01-27 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2021-01-27 |
| 920 | _ | _ | |l yes |
| 920 | 1 | _ | |0 I:(DE-Juel1)INM-2-20090406 |k INM-2 |l Molekulare Organisation des Gehirns |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a UNRESTRICTED |
| 980 | _ | _ | |a I:(DE-Juel1)INM-2-20090406 |
| 980 | 1 | _ | |a FullTexts |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|